Open AccessCirculating free DNA concentration as a marker of disease recurrence and metastatic potential in lung cancer
Author(s) -
MirtavoosMahyari Hanifeh,
GhafouriFard Soudeh,
Khosravi Adnan,
Motevaseli Elahe,
EsfahaniMonfared Zahra,
Seifi Sharareh,
Salimi Babak,
Oskooei Vahid Kholghi,
Ghadami Mohsen,
Modarressi Mohammad Hossein
Publication year - 2019
Publication title -
clinical and translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 1
ISSN - 2001-1326
DOI - 10.1186/s40169-019-0229-6
Subject(s) - medicine , lung cancer , biomarker , oncology , cell free fetal dna , cancer , stage (stratigraphy) , lung , dna , circulating tumor dna , gastroenterology , pathology , biology , pregnancy , paleontology , biochemistry , fetus , genetics , prenatal diagnosis
Background Plasma circulating cell‐free (cf) DNA is regarded as a source of tumor DNA. Based on availability of blood tissue for the purposes of early detection of cancer and patients’ follow‐up, several studies have evaluated concentration of cf DNA in cancer patients in association with tumor features. In the present study, we assessed concentration of cf DNA in lung cancer patients with two commercial kits (MN and QIAGEN) to find whether it can be used as a prognostic biomarker. Results Primary cf DNA concentrations as measured by QIAGEN kit was significantly higher in patients who died in the follow‐up period compared with alive patients (P = 0.007). Moreover, the concentrations as measured by both methods were higher in patients who experienced recurrence in the follow‐up period compared with patients without recurrence (P = 0.008 and 0.007 for MN and QIAGEN kits respectively). Significant associations were also found between cf DNA concentrations and tumor stage (P = 0.005 and 0.02 for MN and QIAGEN kits respectively). Notably, cf DNA concentration was higher in metastatic tumors compared with non‐metastatic tumors in association with number of involved organs. Based on the AUC values, both kits could differentiate metastatic cancers from non‐metastatic ones with accuracy of 98%. Conclusions The current study highlights the accuracy of cf DNA concentrations for prediction of disease course in lung cancer patients.